Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer
Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.
Improved Patient Selection Will Pave the Way for ADC Optimization in HER2-Low and -Ultralow Breast Cancer
Erika P. Hamilton, MD, discusses the implications of the DESTINY-Breast06 trial for patients with HER2-low and -ultralow breast cancer.
Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm
Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.
Dr Curigliano on the Implications of T-DXd in HR+, HER2-Low and -Ultralow Breast Cancer
Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.
Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.
Dr Bardia on the Limitations of HER2 Testing Assays in HER2-Low and -Ultralow Breast Cancer
Aditya Bardia, MD, MPH, FASCO, discusses HER2 IHC testing in patients with HER2-low and -ultralow metastatic breast cancer.
Dr Bardia on Current Approaches to HER2+ Breast Cancer Management
Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer management approaches.
Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer
Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.
Advancements in HER2-Directed Therapies Abound for HER2+ Metastatic Breast Cancer
Aditya Bardia, MD, MPH, FASCO, discusses the evolving role of T-DXd for patients with HER2-positive advanced breast cancer.
Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer
Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma
Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma
